Insider · CIK 0001739761
John Lacey III
Files at PVCT (PROVECTUS BIOPHARMACEUTICALS, INC.). First filing -, latest -.
In brief
John Lacey III files SEC Form 4 as director at PVCT (PROVECTUS BIOPHARMACEUTICALS, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; John Lacey III has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | AGrant or award Series D-1 Convertible Preferred Stockderivative | +48,917 | $0.00 | $0 | 228,509 | Jun 30, 2026 |
| Dec 2, 2024 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | AGrant or award Stock Options (Right to Buy)derivative | +775,082 | $0.00 | $0 | 775,082 | Dec 4, 2024 |
Questions about John Lacey III
Answered from the filings on this page, as of the latest one.
Is John Lacey III buying or selling?
John Lacey III has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did John Lacey III's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and John Lacey III has 0.
Where does John Lacey III file Form 4?
John Lacey III has filed Form 4 at PVCT (PROVECTUS BIOPHARMACEUTICALS, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.